VALEURS À SUIVRE - STOCKS TO WATCH 

Twitter: @TradingPharma

"Confirmation of the rising stock prices"

20/03/2017

AB SCIENCE 17.36 (c) +13.32% Volume 1 333 216

AB Science announces positive top-line results of final analysis from study AB10015 of masitinib in amyotrophic lateral sclerosis (ALS)20/03/2017 - Primary analysis is a success and confirms interim analysis

17/03/2017

GENFIT 32.85 (c) -2.23% 1 month +54.88% Capitalization 1 023.82 MEUR

13/03/2017

GENFIT 33.13 (c) +13.38% Volume 1 276 388  - La résistance est dépassée

INNATE PHARMA 11.78 (c) +7.29% Volume 1 405 165 Extension de l’essai de Phase I/II évaluant lirilumab en combinaison avec nivolumab dans différentes tumeurs solides avancées - Expansion of Phase I/II trial evaluating lirilumab in combination with Opdivo (nivolumab) in patients with advanced solid tumors

06/03/2017-10/03/2017

CERENIS Variation 5 jours -2.35%, 1 mois -72.67% : JP Morgan AM est sorti du capital - Alta California Management Partners IV s'allège au capital - Sofinnova Partners s'allège au capital (Source CF)

GENFIT Variation sur 5 jours +2.89% 1 mois +35.72%

03/03/2017

SANOFI 83.59 (c) +1.15 Volume 2 269 713 (c) Variation 1 month +10.51% 

Sanofi and Regeneron Announce Presentation of Positive Data from Long-Term Pivotal Phase 3 CHRONOS Study of Dupixent® (dupilumab) in Moderate-to-Severe Atopic Dermatitis. The Dupixent Biologics License Application (BLA) was accepted for Priority Review by the U.S. Food and Drug Administration (FDA) with a target action date of March 29, 2017.

Genfit bondit, un possible rachat par Novartis évoqué (Reuters) - Streetinsider reports Swiss drugmaker Novartis is in talks to acquire Genfit - 02/03/17 GENFIT 27.60(c) +29.64% Volume 2 763 561

Cerenis Therapeutics annonce les résultats de l’étude de Phase II CARAT. Pas de différence statistique observée entre le traitement et le placebo - Cerenis Therapeutics Announces Top line Results of CARAT Phase II Study. No statistical difference observed between CER-001 and placebo - 02/03/17 CERENIS 1.70(c) -78.06% Volume 14 327 726 - 03/03/17 2.05 (c) +20.59% Volume 6 183 159

21/02/2017

NEOVACS 0.97(c) +16.87% Volume 18 593 588 + Haut 1.12

NEOVACS SIGNE UN CONTRAT D’OPTION DE LICENCE AVEC BIOSENSE GLOBAL LLC D’UN MONTANT DE 65M€, AUXQUELS S’AJOUTENT DES ROYALTIES, POUR LES DROITS DE DEVELOPPEMENT ET COMMERCIALISATION EN CHINE DE L’IFNα KINOIDE DANS LE LUPUS ET LA DERMATOMYOSITE -  NEOVACS AND BIOSENSE SIGN OPTION AGREEMENT WORTH UP TO €65 MILLION PLUS ROYALTIES FOR CHINESE DEVELOPMENT AND COMMERCIAL RIGHTS TO IFNα KINOID FOR LUPUS AND DERMATOMYOSITIS     

17/02/2017

PIXIUM VISION 7.25 (c) EUR +10.52% Variation 5 days +20.63%

(16/02/2017) PIXIUM VISION announces first implantation and activation of IRIS® II in Spain. The prestigious Institute of Ocular Microsurgery in Barcelona implanted the first patient in Spain with IRIS® II, a bionic vision system equipped with a bio-inspired camera and a 150-electrode epi-retinal implant that is designed to be explantable.

09/02/2017

POXEL's stock falls after analyst downgrade (Socité Générale), price target cut (4.5 €) 5.31 (c) -4.32% Volume 247 998 Variation 5 days -17.42%

07/02/2017

AB SCIENCE 14.52 (c) +8.44% Volume 133 998

Pending Phase III results of masitinib in ALS expected in Q1 2017

CELLECTIS 18.71 2.30% Volume 229 916

La FDA autorise l'entrée en développement clinique d'UCART123, le candidat médicament CAR-T allogénique « sur étagère » de Cellectis ciblant des tumeurs hématologiques (LAM et LpDC) - FDA Grants Cellectis IND Approval to Proceed with the Clinical Development of UCART123, the First Gene Edited Off-the-Shelf CAR T-Cell Product Candidate developed in the U.S.

INNATE PHARMA 10.65 -3.62% Volume 813 635 Variation 5 days -20.16%

06/02/2017

INNATE PHARMA 11.05 (c) -15.65%Volume 3 058 687  Supports: 10.5 then 9.6 €

Innate Pharma annonce les résultats principaux de l’étude EffiKIR évaluant l’efficacité de lirilumab en monothérapie chez des patients âgés atteints de leucémie aigüe myéloïde - L’étude n’a pas atteint le critère primaire d’efficacité - Innate Pharma announces top-line results from EffiKIR trial evaluating the efficacy of lirilumab as a single agent in elderly patients with acute myeloid leukemia - The study did not meet the primary efficacy endpoint

31/01/2017

Biotech Sell-Off - Individual investors may stay away from biotech & drug stocks during turbulent times: drug prices, regulations, drug manufacturing,...

30/01/2017

13.88 (c) -3.74% Volume 143 400 Variation 1 month -6.34% 3 months +36.88%

AB Science émet 520.000 actions nouvelles représentant 1,35% de son capital (12/01/2017) - AB Science launches a share capital increase issuing 520.000 new shares (01/12/2017). Pending Phase III results of masitinib in ALS expected in Q1 2017

27/01/2017

ADOCIA 27.60 (c) -31.46% Volume 579 900 Variation 1 month -52.82%

Adocia annonce la décision d’Eli Lilly de mettre fin à la collaboration sur BioChaperone Lispro - Adocia announces the termination by Eli Lilly of the collaboration on BioChaperone Lispro

CELLECTIS - Gene-edited cells keep cancer babies well more than one year on Reuters (01/25/2017)

26/01/2017

16:03 CELLECTIS 17.00 +1.92% Volume 80 966 - Gene-edited cells keep cancer babies well more than one year on Reuters (Wed Jan 25, 2017)

25/01/2017

ADOCIA: Rebound +12.43% Volume 242 009 (01/24/2017 -11.92% Volume 274 819)

-16.47%  Volume 371 913 TXCELL Launches a Capital Increase of around 11 Million Euros with Shareholders' Preferential Subscription Rights

24/01/2017

16:17 ADOCIA 35.90 -12.65% Volume 207 214 Variation Janv 1st -41.21% 

Adocia annonce l’évolution de son modèle économique afin d’augmenter la valeur de ses projets - ADOCIA announces the transformation of its business model to increase the value of its projects (01/23/2017)

20/01/2017

AB SCIENCE Variation 3 days -8.07% - CELLECTIS Variation 5 days -3.70% - CELYAD Variation 2 days -7.72% Profit Taking

ADOCIA 44.10 (c) -2.43% Variation 5 days -12.95% Adocia announces the transformation of its business model to increase the value of its projects

18/01/2017

14:11 CELYAD 23.650 +8.24% Volume 106 432 Variation 5 days +28.57%

"Analyst says Celyad takes lead in CAR-T for solid tumors" FierceBiotech

16/01/2017

17:01 GENTICEL 2.41 +12.62% Volume 610 641

(22/12/2016) Genticel and Genkyotex Announce Intention to Enter into Strategic Combination - Genkyotex is a pioneer in discovery and development of NOX therapeutics

16:38 GUERBET 84.20 +6.34% Variation 6 months +55.22%

As a reminder: 27/11/2015 Guerbet completes acquisition of Mallinckrodt’s Contrast Media and Delivery Systems business (CMDS) - Acquisition creates a global leader specializing in contrast media and imaging solutions and services (ISS)

16:15 CELYAD 20.760 +6.24% Volume 49 456  Variation 5 days +9.21%

13/01/2017

CELYAD 19.540 (c) +5.05% Volume 30 140

"Analyst says Celyad takes lead in CAR-T for solid tumors" FierceBiotech

Celyad Announces Registration of the First Pancreatic Cancer Patient in its CAR-T NKR-2 THINK Trial in Belgium (11/01/2017)

12/01/2017

PIXIUM VISION 7.02 (c) +6.53% Volume 51 173

Pixium Vision achieves implantation of 10 patients in its clinical trial with its innovative 150 electrodes IRIS® II bionic vision system

11/01/2017

Wall St. recovers after Trump's comments hit drug stocks Reuters Health

"We expect the U.S. biotech and pharmaceutical sector to be very volatile in the coming days and any mergers and acquisition will not be that easy," said Naeem Aslam, chief market analyst at ThinkMarkets UK.

Drug Stocks Plunge as Trump Threatens to Force Price Bidding Bloomberg Markets

‘"We’re going to save billions,’ Trump says of bidding plans- Biotech index drops 2.6%, large drugmaker stocks down 1.7%

After the election, he told Time Magazine “I’m going to bring down drug prices.”

05/01/2017

CELLECTIS 18.45 (c) +2.10% Volume 134 930  Variation sur 5 jours +13.82%

Servier signe une nouvelle alliance dans l'immuno-oncologie avec une biotech américaine

AB SCIENCE 16.30 (c) -2.98% Volume 372 905 & VISIOMED GROUP 2.87 (c) -10.31%  Profit Taking

04/01/2017 

CELLECTIS 18.07(c) +3.02% Volume 180 991

09:06 AB SCIENCE 17.61 +13.03% Volume 131 250 13:16 16.86 +8.22% Volume 639 600 - 16.80 (c) +7.83% Volume 835 772

Dans l'attente d'importants "catalyseurs" : Résultats définitifs de l’étude de phase III du masitinib dans la sclérose latérale amyotrophique et, premier trimestre 2017, la réponse de l’agence européenne du médicament sur l’utilisation du masitinib dans la mastocytose

New preclinical data demonstrate that masitinib has an unexpected protective effect on muscles and nerves in Amyotrophic Lateral Sclerosis 03/01/2017 - These new data have been presented at the 27th International Symposium on ALS/MND in December 2016 in Dublin, Ireland.

09:09 VISIOMED GROUP 3.22 -5.29% Profit Taking Variation Jan +41.85% - 3.20(c) -5.88% Volume 1 514 627

03/01/2017 AB SCIENCE +5.13% CELLECTIS +6.30% VISIOMED GROUP +11.48%

CELLECTIS a soumis une demande d’essais cliniques pour UCART123 un produit allogénique fondé sur des cellules CART ingéniérées ciblant des tumeurs hématologiques (LAM et LpDC) - CELLECTIS Submits IND Application for UCART123, an Allogeneic Gene Edited CAR T-Cell Product Candidate, in AML and BPDCN

VISIOMED GROUP : CES 2017 - Annonce n°1 : VISIOMED GROUP révolutionne la télémédecine avec VISIOCHECK(R), la première station de télémédecine mobile et connectée au monde de moins de 300 grammes


2016


29/12/2016 10:27

AB SCIENCE 13.86 +2.59% ADOCIA 59.83 +2.27% CELLECTIS 16.29 +0.56% OSE IMMUNO 7.67 +2.27%

28/12/2016

OSE Immunotherapeutics 7.50 (c) +21.36%

OSE Immunotherapeutics signe une option de licence avec Servier pour le développement et la commercialisation du produit Effi-7 - OSE Immunotherapeutics signs a license option agreement with Servier to develop and commercialize the product Effi-7

ADOCIA 58.50 (c) +6.75% Variation 1 week +12.24% - AB SCIENCE 13.51 (c) +4.16% Variation 1 week +7.74% 1 month +29.78%

19/12/2016. INNATE PHARMA 14.45 (c) +7.51% Volume 888 028 - CELLECTIS 16.20 (c) -3.17% Variation 1 week -0.86% 3 months -25.35%

INNATE PHARMA announces key leadership and corporate governance changes to support next stage of development

16/12/2016 SANOFI 74.39 (c) -2.12% Volume 9 900 036 - 19/12/2016 74.86 (c) +0.63% Volume 3 064 950

Sanofi Said to Be in Advanced Talks to Acquire Actelion Bloomberg - Actelion's shares jump on report of Sanofi deal nearing Reuters

15/12/2016 INVESTMENT IDEAS ABOUT BIOTECH STOCKS

AB SCIENCE +16.53%  since 25/11/2016 -  16/12/2016 12.35 (c) +1.90% Volume 151 886

07/12/2016 PROFIT TAKINGS AFTER the 2016 ASH Annual Meeting: CELLECTIS, CELYAD, & INNATE PHARMA

06/12/2016

CELLECTIS 16.39 (c) +1.42% Volume 128 083 CELYAD 19.30 (c) +2.06% Volume 57 873 Variation 5 days +12.01%

04/12/2016 

CELLECTIS 15.80 -0.44% Volume 81 240 - 05/12/2016 16.16 (c) +2.28% Volume 101 593

07/11/2016 CELLECTIS Announces Two Oral Presentations and One Poster at the 2016 ASH Annual Meeting. The meeting will be held December 3-6, 2016 in San Diego.

INNATE PHARMA 13.63 (c) -0.15% Volume 428 184 - 05/12/2016 14.10 (c) +3.45% Volume 336 138

Oral presentation (2016 ASH Annual Meeting), entitled “First-in-Human, open label, multicenter phase I study of IPH4102, first-in-class humanized anti-KIR3DL2 mAb, in relapsed/refractory CTCL: preliminary safety and clinical activity results

01/12/2016

15:33 TXCELL 3.21 +42.67% Volume 287 169 - 15:37 3.00 +33.33% - 2.75 (c) +22.22% Volume 520 345

TxCell aligne sa structure opérationnelle avec sa réorientation stratégique - TxCell completes aligning operations with strategic refocus (11/29/2016)

11:29 GENTICEL 3.35 +12.79% Volume 2 599 761 Variation 5 days +139.86% - 3.25 (c) +9.43% Volume 7 450 401

30/11/2016

CELYAD 17.230 (c) -8.84% Volume 156 701

09:35 GENTICEL 1.96 +50.77% Volume 822 156 - GENTICEL 2.97 (c) +128.46% Volume 6 157 361

GENTICEL franchit une étape déterminante de son partenariat avec Serum Institute concernant l'utilisation de GTL003 dans des vaccins multivalents - GENTICEL successfully completes determining milestone in partnership with Serum Institute regarding use of GTL003 in multivalent vaccines

29/11/2016 Biotechs: Periods of Volatility Calendar: Italian constitutional referendum 04/12/2016, ECB Meeting 08/12/2016, & FED Meeting 14/12/2016

28/11/2016 Trading in Low Volumes

12:28 CELYAD 20.195 +2.25% 19.900 (c) +0.76% Vol 48 403

12:20 AB SCIENCE 10.30 -0.96% ABIVAX 7.81 +2.63%  CELLECTIS 17.05 +0.95% INNATE PHARMA 14.66 +3.24% - AB SCIENCE 10.34 (c) -0.58% Volume 43 535 ABIVAX 7.60 (c) -0.13% Volume 42 172 CELLECTIS 16.59 (c) -1.78% Volume 40 787 INNATE PHARMA 14.64 (c) +3.10% Volume 377 761

25/11/2016

INNATE PHARMA French cancer specialist Innate Pharma can remain independent, for now: CEO Reuters

AB SCIENCE 10.40 (c) +3.28% Volume 89 091 - Support court terme 9.9 - Résistance court terme 10.7

Pending Results from Phase III Trial of Masitinib in ALS: Q1 2017

ABIVAX 7.61 (c) +8.71% Volume 24 296 Variation 3 months + 89.30%

ABIVAX organise un déjeuner investisseurs avec des leaders d’opinion qui portera sur les nouvelles approches thérapeutiques pour lutter contre le VIH - ABIVAX to Host Key Opinion Leader Luncheon for Investors Focused on Novel Approaches to HIV Therapy November 28, 2016 in New York

CELYAD 9.75 (c) +5.47% Volume 49 811 Variation 5 days +15.63% Price Target: 36 EUR (Source Portzamparc)

November 21, 2016 CELYAD announces the approval to initiate its NKR-2 CAR-T Clinical Trial in Belgium

November 07, 2016 CELYAD’s NKR-2 Phase I safety trial delivers encouraging results to be presented at ASH 2016

BOIRON "World Leader in Homeopathic Medicines" 83.13 (c) -0.07%

Homeopathic Medicines Will Carry Labels Saying They’re Unscientific Slate Nov. 16 2016

21/11/2016 CELLECTIS 16.55 (c) -3.37% Variation 5 days -5.99%

18/11/2016 CELLECTIS 17.23 (c) -3.31% Volume 145 070

17/11/2016 CELLECTIS 17.82 (c) -7.38% Volume 178 682

16/11/2016 11:35 CELLECTIS 18.83 +6.32% Volume 113 004 - 19.24 (c) +8.64% Volume 322 312

Cellectis Announces Successful cGMP Manufacturing for Second Product Candidate: UCART123

Cellectis annonce avoir réalisé avec succès les campagnes de production de son second produit candidat UCART123 selon les Bonnes Pratiques de Fabrication (BPF)

15/11/2016

09:53 ERYTECH PHARMA 13.49 -22.78% Volume 158 745 - 13.25 (c) -24.16%

ERYTECH Announces Withdrawal of Its European Marketing Authorization Application for GRASPA for Acute Lymphoblastic Leukemia and Prepares for Resubmission

Withdrawal of European Marketing Authorization Application (MAA) for eryaspase (GRASPA®); additional data requested by the Committee for Human Medicinal Products (CHMP) will take more time to provide than allowed in the CHMP’s approval procedures - Intention to resubmit the MAA mid-2017

15/11/2016

TRANSGENE

Transgene presents preclinical results of TG1050, an HBV-targeted immunotherapy, at AASLD 2016 Liver Meeting

"Poster title: TG1050, an HBV-targeted immunotherapeutics, efficiently decreases HBV viremia and antigenemia in a preclinical model; a meta-analysis and the determination of the involvement of CD4 and CD8 T cells."

14/11/2016

13:56 NANOBIOTIX 15.70 +15.87% Volume 260 855 15.65 (c) +15.50%

13:47 INNATE PHARMA 14.40 +8.03% Volume 1 046 340 13.13 (c) -1.50%

09:09 INNATE PHARMA 3.85 +3.90% Volume 149 294

Innate Pharma investor conference call on November 14, 2016 to discuss recent new clinical data

SITC: efficacy data for lirilumab in combination with nivolumab
ESMO: safety data for lirilumab in combination with nivolumab or ipilimumab
3WCCL: preliminary clinical data for IPH4102

09:03 NANOBIOTIX - SITC 2016 - 14.23 +5.02%

NANOBIOTIX PRESENTS NBTXR3 PRECLINICAL DATA DEMONSTRATING ITS POTENTIAL USAGE AS IN SITU VACCINE FOR CANCER AT THE SOCIETY FOR IMMUNOTHERAPY OF CANCER ANNUAL MEETING

13/11/2016 INNATE PHARMA - SITC 2016

Bristol-Myers Squibb, Inc., Innate Pharma SA, Marseille, France, and Ono Pharmaceutical Company Limited, Osaka, Japan

Preliminary efficacy from a phase 1/2 study of the natural killer cell–targeted antibody, lirilumab in combination with nivolumab in squamous cell carcinoma of the head and neck

11/11/2016 INNATE PHARMA 13.33 +3.65% Volume 731 667  Variation 5 days +20.31%

10/11/2016 A second straight day of gains after Trump victory: CELLECTIS +11.90% & INNATE PHARMA +12.12%

Les Echos - Les biotechs françaises profitent de l’élection de Donald Trump par Sacha Pouget, Président de Kalliste Finance et fondateur de BiotechBourse.fr

09/11/2016 "Biotech Stocks Jump as Donald Trump Clinches Presidency in Major Upset" BioSpace - The medical technology sector is down for fear of protectionism

Le secteur gagnant au terme de l'élection, du point de vue des investisseurs : le secteur pharmaceutique - "Le pire scénario pour l'industrie du médicament (une baisse des prix des médicaments), d'une victoire démocrate, n'est plus sur la table", écrivent dans une note les analystes du gestionnaire d'actifs Candriam. (Source AFP)

08/11/2016

PIXIUM VISION +16.70% annonce la réussite, au Royaume Uni, de la première implantation et activation d'IRIS®II, système de vision bionique - PIXIUM VISION +16.70% announces the first successful implantation and activation of IRIS® II, 150 electrode bionic vision system, in the UK

World renowned Moorfields Eye Hospital in London implanted the first patient with IRIS® II, a bionic vision system equipped with a bio-inspired camera and a 150 electrode epi-retinal implant that is designed to be explantable. Business Wire

08/11/2016 13:34

15.18 +1.27% Cellectis Announces Two Oral Presentations and One Poster at the 2016 ASH Annual Meeting - The meeting will be held December 3-6, 2016 in San Diego

11.33 + 2.26% Innate Pharma’s drug candidates at SITC annual meeting National Harbor (MD) USA 09/11/2016 to 13/11/2016

07/11/2016

14:53 CELYAD 15.805 +6.04% Volume 14 833

Celyad’s NKR-2 Phase I safety trial delivers encouraging results to be presented at ASH 2016

14:51 ONXEO 2.38 +3.48% Volume 223 515

Onxeo annonce des résultats précliniques prometteurs de Livatag® dans le cancer du pancréas - Onxeo Announces Promising Results from Preclinical Studies of Livatag® in Pancreatic Cancer

06/11/2016 Part III - Would Hillary Clinton Be Bad for Biotech Stocks? - Wall Street is jittery over how the Democratic nominee might treat the biotech industry. But should it be?

Part II - Les Conséquences du Brexit sur les Biotechs 24/06/2016 "Brexit" 27/06/2016 Post "Brexit"

Part I - Les Conséquences du Brexit sur les Biotechs 13, 14, & 16 juin - Les sondages donnent le "Brexit" en tête 

04/11/2016

HYBRIGENICS - 0.76 (c) 7.04% Volume 303 679

HYBRIGENICS présentera de nouveaux résultats in vitro sur l'inécalcitol dans le myélome multiple et dans la leucémie myéloïde aiguë au congrès annuel de l'ASH à San Diego, aux Etats-Unis - HYBRIGENICS will present new in vitro results on inecalcitol in multiple myeloma and acute myeloid leukemia at the annual ASH meeting in San Diego, USA

GENFIT : Approbation officielle de l'IND par la FDA pour l'essai clinique de Phase II évaluant elafibranor dans la CBP

Approbation de la demande d'IND par la FDA pour la nouvelle indication d'elafibranor dans la Cholangite Biliaire Primitive (CBP), maladie rare avec des besoins non satisfaits et seulement deux molécules au statut de médicament orphelin approuvées à ce jour

03/11/2016

GENFIT 18.90 (c) +6.63% Volume 546 777

BONE THERAPEUTICS 8.273 (c) +19.90% Volume 89 459

Bone Therapeutics Notice of Q3 2016 Results - Results to be announced on 8 November 2016

INNATE PHARMA 11.05 (c) +4.44% Volume 289 312 - CA à neuf mois multiplié par 2.5 - Oddo & Portzamparc restent à l'Achat - Third quarter 2016 report

02/11/2016 Elections US : Quelles Conséquences pour les Biotechs ? Why Biotech Investors Are Terrified of the Upcoming Elections - Major policy changes that negatively impact biotechs could be on the way pending the outcome of the November elections. The Motley Fool, Keith Speights October 16, 2016.

28/10/2016 

SANOFI - 71.43 (c) +3.73% Volume 7 101 222

Sanofi et Regeneron reçoivent une lettre de réponse complète de la FDA au sujet du sarilumab, leur traitement expérimental de la polyarthrite rhumatoïde ​ - Sanofi and Regeneron Receive Complete Response Letter from FDA for Sarilumab, an Investigational Treatment for Rheumatoid Arthritis

AB SCIENCE 10.17 (c) +0.59% CELLECTIS 16.42 (c) -2.84% INNATE PHARMA 11.04 (c) -2.65%                           

28/10/2016 11:55 AB SCIENCE 10.15 +0.40% Volume 23 102, pending Phase III clinical results of masitinib in the treatment of amyotrophic lateral sclerosis (ALS) (end of 2016 - beginning 2017)

28/10/2016 11:17 SANOFI 73.72 +7.06% Volume 3 269 476 (vide infra 03/10) - 71.43 (c) +3.73%

Sanofi annonce de solides résultats au T3 2016 - Sanofi Announces Strong Q3 2016 Results

Sanofi prépare la vente des génériques en Europe

27/10/2016 09:41 INNATE PHARMA 11.22 +1.81% Variation 5 days + 6.35% - 11.34 (c) +2.90% Volume 491 074 (vide infra 19/10)

Résultats préliminaires encourageants pour IPH4102 présentés au Congrès Mondial des Lymphomes Cutanés  - Encouraging initial results for IPH4102 presented at the Third World Congress of Cutaneous Lymphomas

25/10/2016 DBV Technologies 67.82 (c) +5.00% Volume 88 004 Variation 5 jours +2.65%: Les Premiers Résultats de l’Étude de Suivi de deux ans de Viaskin® Peanut montrent un niveau de désensibilisation élevé et durable à l’arachide - Topline Results from Two-Year Follow-Up Study of Viaskin Peanut Show Long-Lasting and High Levels of Desensitization to Peanut

AB SCIENCE 10.30 (c) 0.00% Volume 78 747 Variation 5 jours -0.39% CELLECTIS 16.68 (c) -2.46% Volume 79 380 Variation 5 jours -4.85% INNATE PHARMA 10.74 (c) +1.51% Volume 205 468 Variation 5 jours +1.70%

19/10/2016 AB SCIENCE 10.34 (c) -2.91% CELLECTIS 17.53 (c) -2.07% INNATE PHARMA 10.56 (c) -1.49% POXEL 6.10 (c) -4.39% Variation 5 jours -4.85%

19/10/2016 09:52 INNATE PHARMA 10.68 -0.37% Volume 58 867 - Lirilumab: Monotherapy & Combination

1. Lirilumab: First-in-class anti-KIR mAb licensed to Bristol-Myers Squibb - LFS expected 2Q 2016

Efficacy Study of Anti-KIR Monoclonal Antibody as Maintenance Treatment in Acute Myeloid Leukemia (EFFIKIR) (EFFIKIR)

2. The combination of lirilumab and nivolumab in a phase I study of advanced solid tumors. Efficacy data will be presented at the Society for Immunotherapy of Cancer 2016 conference. Welcome to the SITC 2016! November 9-13, 2016

19/10/2016 09:26

POXEL 6.11 -4.23% Volume 83 791 High Volatility

18/10/2016

POXEL 6.38 (c) +7.95% Volume 604 198

Jefferies a initié mardi le suivi du titre Poxel avec une recommandation d'achat et un objectif de cours de 12 €. Le broker américain met en avant le profil 'unique' de l'Imeglimine. - Jefferies has a Buy rating for POXEL with a  €12 price target. The broker highlights the unique profile of Imeglimine.

AB SCIENCE 10.65 (c) 0.00% CELLECTIS 17.90 (c) -0.67%

17/10/2016

POXEL 5.91 (c) EUR -3.43% Volume 179 510 - The biotech is down about 10% on the last five days - Still under pressure

CELLECTIS 18.02 (c) EUR -2.65% Volume 56 977 Variation 5 days -10.30%

14/10/2016 AB SCIENCE 10.52 (c) +1.94% Volume 87 927 CELLECTIS 18.51 (c) -1.02% Volume 57 620 - Trading in Low Volumes

GENFIT 18.850 (c) +4.40% Volume 402 929 Technical Rebound - Genfit successfully raises 33.9 million euros in private placement - 1,695,000 new ordinary shares at a price of 20.00 euros per share - Offering represents 6.4 pct of pre-transaction share capital - Tout savoir sur les augmentations de capital - La décote (Source Boursier.com)

13/10/2016

AB SCIENCE 10.32 (c) -3.46% Volume 121 081 "Masitinib represents a new drug candidate for the treatment of ALS"

11/10/2016 Masitinib significantly slows disease progression in post-paralysis SOD1G93A rats and reduces inflammation in both CNS and PNS - 03/10/2016 AB Science has been invited at four international meetings to present new preclinical data showing neuroprotective effect of masitinib in amyotrophic lateral sclerosis (ALS)

CELLECTIS 18.70 (c) -4.25% Volume 111 141

U.S. patent 9,458,439: "This pivotal invention is at the basis of current nuclease-based precise gene inactivation techniques using chimeric restriction endonuclease such as Cas9/CRISPR (and related families), Zinc finger Nucleases, TAL-Effector Nucleases, Mega-TALEs, some Meganucleases i.e. endonucleases generated by the juxtaposition of specific DNA binding sequences and DNA cleavage domains with a recognition site of at least 12 base pairs."

12/10/2016 The Biotech Sector is in a Downward Trend -  the three main points of risk in biotech: trail failure, commercial failure, and patent expiration (Source The Motley Fool, Todd Campbell, Mar 13, 2016

10/10/2016 12/15 CELLECTIS 19.95 -1.63% Volume 14 692 - 20.45 (c) +0.84%

Cellectis annonce la délivrance par l'USPTO du brevet U.S. 9,458,439 qui s’ajoute au brevet U.S. 8,921,332 délivré en décembre 2014 - Cellectis Announces the Issuance of U.S. Patent 9,458,439 Following U.S. Patent 8,921,332 Issued in December 2014 (10/04)

This issued U.S. patent 9,458,439 claims the method of introducing chromosomal modifications at a locus by induction of double-stranded DNA cleavage using a chimeric restriction endonuclease and non-homologous end joining recombination (NHEJ).

10/10/2016 10:36 GENFIT 20.260 -4.57% Volume 215 580 - 20.675 (c) -2.61%

GENFIT lève avec succès 33.9 millions d'euros par placement privé - GENFIT successfully raises 33.9 millions d'euros in private  (05/10/2016)

07/10/2016 AB SCIENCE 11.17 (c) -2.95% Vol 89 827 CELLECTIS 20.28 (c) 0.10% Volume 54 024 INNATE PHARMA 11.01 (c) -3.93% Volume 550 120

06/10/2016 GENFIT - Cotation suspendue - Suspension of the trading of Genfit shares 21.30 (c) -11.34%

GENFIT lance une augmentation de capital par placement privé - GENFIT lauches a share capital increase through private placement

06/10/2016 12:54 TRANSGENE 2.94 +4.26% Volume 357 553 - 2.90 (c) +2.84%

Transgene présente une nouvelle génération de virus oncolytique ayant une plus grande capacité cytotoxique sur des cellules tumorales résistantes grâce à l’expression d’anticorps intracellulaires -  Transgene presents data on improved cytotoxic activity of oncolytic viruses expressing intrabodies in resistant tumor cell lines

04/10/2016 INNATE PHARMA 11.67 (c) +6.77% Volume 589 340

Poursuite de l’essai EffiKIR sans modification après la septième évaluation du comité de revue des données et de la tolérance. Le recrutement des patients dans l’étude s’est achevé en juillet 2014. L’analyse du critère primaire d’efficacité, la survie sans leucémie, est de type « event driven » et pourrait avoir lieu avant la fin 2016. - Seventh data and Safety Monitoring Board Meeting of the EffiKIR trial recommends continuation without modification. Enrolment in the EffiKIR study was completed in July 2014. The analysis on the primary endpoint, leukemia-free survival, is event driven and could occur by the end of 2016.

04/10/2016 16:05 CELLECTIS 20.73 -0.10% Volume 88 189 Variation 5 days -6.45% - 20.63 (c) -0.58%

04/10/2016 09:05 NOVACYT 1.38 +7.81% Volume 121 331 - 1.38 (c) 7.81%

SANOFI - Le vaccin contre la dengue approuvé dans 11 pays - SANOFI's dengue vaccine approved in 11 countries

NOVACYT signe un accord stratégique avec Cepheid pour le diagnostic HPV en Amérique Latine - NOVACYT signs strategic alliance with Cepheid for HPV diagnostics in Latin America

03/10/2016 14:15 NICOX 8.92 +9.03% Volume 407 464 - 8.75 (c) +6.88%

En attente de toutes nouvelles informations relatives à l’approbation du latanoprostene bunod par la FDA - Waiting for information relating to the approval of latanoprostene bunod by the FDA

03/10/2016 12:22 SANOFI 68.22 +0.86% Volume 340 955

Sanofi et Regeneron annoncent la publication dans le New England Journal of Medicine des données positives de phase 3 du Dupixent® (dupilumab) dans le traitement de la dermatite atopique - Sanofi and Regeneron Announce Positive Dupixent® (dupilumab) Phase 3 Atopic Dermatitis Data Published in The New England Journal of Medicine​ (10/01/2016)

30/09/2016 12:58 AB SCIENCE 12.12 +4.03% Volume 215 116 - 11.86 (c) +1.80%

Filing of masitinib in the treatment of amyotrophic lateral sclerosis to the European Medicine Agency (EMA). The review process started on 12 September 2016.                           

30/09/2016 12:34 QUANTUM GENOMICS 8.27 +24.74% Volume 621 006 - 7.90 (c) +19.16%

Quantum Genomics annonce des résultats positifs pour l’étude clinique de phase IIa de QGC001 dans l’hypertension artérielle (29/09/2016) -  Quantum Genomics reports positive top-line results from Phase IIa trial of QGC001 in hypertension

ONXEO 2.60 -14.19% Volume 1 701 808 - 2.51 (c) -17.16%

Réussite de l'augmentation de capital (12.5 M euros)  - Successful capital increase

28/09/2016 09:36 ONCODESIGN 16.65 EUR +7.28% Volume 13 649 - 15:29 18.36 18.30% Volume 101 574 15:58 18.74 +20.75% Volume 106 358  18.03 (c) +16.17%

27/09/2016 SANOFI 67.94(c) +0.52% 

​FDA set to decide on two likely blockbuster drugs by Sanofi Genzyme (Boston Journal Business): dupilumab (treatment for eczema, a chronic inflammatory skin disease also known as atopic dermatitis) & sarilumab (treatment for rheumatoid arthritis)

ONCODESIGN 15.52(c) -0.26%

Oncodesign annonce l'acquisition du centre de recherches de gsk en france (Reuters) - GSK, Oncodesign announce agreement for Oncodesign's acquisition of GSK's research centre in France (Reuters 28/09)

27/09/2016 AB SCIENCE 11.64 (c) -3.00% Volume 66 405 - CELLECTIS 22.16 (c) -1.07% Volume 75 343

27/09/2016 14:36 NICOX 8.492 -5.22% Volume 291 863 Support enfoncé - The support (9.16) has been broken - Support 9.16/7.9 - 8.525 (c) -4.85% Volume 392 565

27/09/2016 13:57 GENFIT under pressure 24.300 -8.30% Volume 378 145 - 23.910 (c) -9.77% Volume 553 085

Le groupe n'a pas trouvé de partenaire financier pour son projet Elafibranor (Source Cercle Finance) - The Biotech has not found financial partners for Elafibranor development project

Résultats du 1er semestre 2016 : Trésorerie de fin de période de 94 M€ et avancées majeures dans le cadre du programme Elafibranor - H1 2016 Results: Cash position at end of period at €94M and significant advances in Elafibranor program

27/09/2016 11:25 SANOFI 68.50 +1.35%

La BARDA accorde 43,2 millions de dollars US à Sanofi Pasteur pour développer un vaccin contre le virus Zika​ - BARDA Grants $ 43.2 million USD to Sanofi Pasteur for Zika​

Sanofi et Regeneron annoncent que la FDA des Etats-Unis a accepté l’examen prioritaire de la demande de licence de produit biologique pour le dupilumab​ - Sanofi and Regeneron Announce Dupilumab Biologics License Application Accepted for Priority Review by U.S. FDA

26/09/2016 AB SCIENCE 12.00 (c) -1.72% Volume 37 885

23/09/2016

AB SCIENCE 12.21 (c) -0.89% Volume 33 899 Variation sur 5 jours +0.49% Support 11.5-10.7 Résistance 13-15.5

GENTICEL 1.77 (c) -14.08% Volume 405 126

23/09/2016 11:57

GENFIT 27.835 +4.21% Volume 294 377  27.380 (c) +2.51%

Identification d’agonistes inverses de RORγt prêts pour le lancement d’études réglementaires pré-IND - Successful identification of RORγt inverse agonists as candidates for regulatory pre-IND studies

GENOMIC VISION 7.78 +11.62% Volume 41 106  7.30 (c) +4.73%

22/09/2016

TRANSGENE 2.98 (c) +2.76% Volume 205 636

GENFIT 26.710 (c) +3.41% Volume 434 480

GENOMIC VISION 6.97 (c) +24.91% Volume 53 570 Variation sur 5 jours +34.30%. Pas de données disponibles - No data available

NICOX 9.231 (c) -3.47% en position d'obtenir de la FDA deux AMM d'ici la fin de 2016

Bausch + Lomb, partenaire licencié de Nicox pour le latanoprostene bunod, a reçu une lettre de réponse (Complete Response Letter) de la FDA américaine concernant son usine de fabrication ; aucun commentaire quant à l’efficacité ou à la sécurité du produit et aucune étude clinique supplémentaire requise pour une autorisation de mise sur le marché. Revue prioritaire en cours par la FDA du dossier de demande d’autorisation de mise sur le marché (NDA) de l’AC-170.

Latanoprostene bunod licensee Bausch + Lomb receives Complete Response Letter from U.S. FDA pertaining to B+L manufacturing facility; no efficacy or safety concerns or additional clinical trials regarding the compound identified for approva. AC-170 NDA under FDA Priority Review approval process

21/09/2016 09:18 TRANSGENE 3.10 +15.24% - 2.90 (c) +7.81%

Futur acteur clé en Immuno-Oncologie - Future key player in Immuno-Oncology. Natixis entame son suivi à l'Achat (Source AOF)

20/09/2016 GENFIT 25.990 (c) +15.51% Volume 1 276 767

Accélération de la hausse du titre Genfit après l'annonce du rachat de Tobira par Allergan

Avancées significatives dans le cadre d’un nouveau programme de qualification de miARNs et d’algorithmes propriétaires pour le diagnostic non-invasif de la NASH - Significant Milestones Achieved under a New Qualification Program of Proprietary miRNAs and Algorithms for a Non-invasive NASH Diagnostic

16/09/2016 JOURNÉE DES 4 SORCIÈRES - QUADRIPLE WITCHING DAY - SPECULATIVE BIOTECH MARKET: ABIVAX -19.80% BIOPHYTIS -18.29% GENTICEL -20.40% TXCELL -16.26% CELLNOVO -8.68% SAFE ORTHOPAEDICS -9.14%

15/09/2016  BIOTECH HIGH: INVESTORS' RETURN ON EVE OF QUADRIPLE WITCHING DAY - NO RECENT NEWS ON PHASE III RESULTS 

ABIVAX 22.98% BIOPHYTIS 83.95% GENTICEL 50.60% SAFE ORTHOPAEDICS 13.64% SENSORION +12.31% TXCELL 32.05%

Abivax : les spéculateurs se ruent sur le titre par Pierre-Louis Germain - Le Revenu

 Analyse Fondamentale
 Analyse Technique
 Analyse Scientifique


CAC 40 - DOW JONES INDUSTRIAL AVERAGE - NASDAQ Composite 
CAC 40 VOLA IDX 
Indicateur de volatilité du CAC 40 - VIX Indicateur de volatilité du marché financier américain
BCE - LES TAUX DIRECTEURS

BLOOMBERG BUSINESS MARKETS
REUTERS EDITION: US
SmarterAnalyst All The Financiel News You Can Trust

WORLDPHARMANEWS - FiercePharma - Forbes Pharma Information

FDA Drugs U.S. Food and Drug Administration Protecting and Promoting Your Health

 


 

 

     

      

"Investing in biotech is an art that requires fluency in both business and science, as well as sophisticated translational skills to connect the two worlds." EcoR1 Capital

Jan 20, 2017 Donald Trump’s first 100 days, and beyond, for biopharma "The shape of things to come for pharma during the next four years will be wrought over the coming weeks" by Ben Adams FierceBiotech

24/03/2017 Clôture. MISE À JOUR DU MARCHÉ - MARKET UPDATE - Twitter: @TradingPharma

20/03/2017 Clôture. MISE À JOUR DU MARCHÉ - MARKET UPDATE

17/03/2017 Clôture. MISE À JOUR DU MARCHÉ - MARKET UPDATE

10/03/2017 Clôture. MISE À JOUR DU MARCHÉ - MARKET UPDATE

03/03/2017 Clôture. MISE À JOUR DU MARCHÉ - MARKET UPDATE

01/03/2017 Clôture. MISE À JOUR DU MARCHÉ - MARKET UPDATE

24/02/2017 Clôture. MISE À JOUR DU MARCHÉ - MARKET UPDATE

17/02/2017 Clôture. MISE À JOUR DU MARCHÉ - MARKET UPDATE

10/02/2017 Clôture. MISE À JOUR DU MARCHÉ - MARKET UPDATE

09/02/2017 Clôture. MISE À JOUR DU MARCHÉ - MARKET UPDATE

07/02/2017 Clôture. MISE À JOUR DU MARCHÉ - MARKET UPDATE

06/02/2017 Clôture. MISE À JOUR DU MARCHÉ - MARKET UPDATE

03/02/2017 Clôture. MISE À JOUR DU MARCHÉ - MARKET UPDATE

31/01/2017 Clôture. MISE À JOUR DU MARCHÉ - MARKET UPDATE

30/01/2017 Clôture. MISE À JOUR DU MARCHÉ - MARKET UPDATE

27/01/2017 Clôture. MISE À JOUR DU MARCHÉ - MARKET UPDATE

25/01/2017 Clôture. MISE À JOUR DU MARCHÉ - MARKET UPDATE

23/01/2017 Clôture. MISE À JOUR DU MARCHÉ - MARKET UPDATE

20/01/2017 Clôture. MISE À JOUR DU MARCHÉ - MARKET UPDATE

17/01/2017 Clôture. MISE À JOUR DU MARCHÉ - MARKET UPDATE

29/12/2016 Clôture. MISE À JOUR DU MARCHÉ - MARKET UPDATE

Support 22/01/2016

 Analyse Fondamentale
 Analyse Technique
 Analyse Scientifique

 

SANOFI - ACTUALITÉS

SANOFI - ACTUALITÉS

Communiqués de presse 2017- 04/03/2017. Sanofi et R[...]
ADOCIA - ACTUALITÉS

ADOCIA - ACTUALITÉS

Communiqués de presse 2017- 07/03/2017. ADOCIA anno[...]
CELLECTIS - ACTUALITÉS

CELLECTIS - ACTUALITÉS

Communiqués de presse 2017- 06/02/2017. La FDA auto[...]
INNATE PHARMA  - ACTUALITÉS

INNATE PHARMA - ACTUALITÉS

Communiqués de presse 2017- 07/03/2017. 2016 : Des [...]

3 BIOTECHS SPECIALISÉES EN ONCOLOGIE

CELLECTIS - ACTUALITÉS - Cours Action CELLECTIS

"Innovative medicine through genome engineering and cell therapies"

INNATE PHARMA - ACTUALITÉS - Cours Action INNATE PHARMA

"Discovering and developing first-in-class therapeutic antibodies for the treatment of cancer and inflammatory diseases"

ONCODESIGN - ACTUALITÉS - Cours Action ONCODESIGN

"Paving the way for a truly personalized approach in cancer"

 

ACTUALITÉS EN ONCOLOGIE sur Targeted Oncology 

Actualités

Vendredi, 17 Mars 2017

Catégorie : Cancer

Extension de l’essai de Phase I/II évaluant lirilumab en combinaison avec nivolumab dans différentes tumeurs solides avancées

[...]

Vendredi, 17 Mars 2017

Catégorie : Cancer

Servier et Pfizer annoncent l’obtention de la part de la FDA de l’autorisation de mener aux Etats-Unis le développement clinique précoce de UCART 19 dans le traitement des leucémies lymphoblastiques aiguës en rechute ou réfractaires chez l’adulte

[...]